The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of prognostic analysis of young breast cancer patients (<35 years of age) based on the Breast Cancer Registry of the Japanese Breast Cancer Society.
 
Akemi Kataoka
No Relationships to Disclose
 
Eriko Tokunaga
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Sanofi
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tadahiko Shien
No Relationships to Disclose
 
Mika Miyashita
No Relationships to Disclose
 
Kimiko Kawabata
No Relationships to Disclose
 
Ai Tomotaki
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Kaketsuken (Inst); NIPRO CORPORATION (Inst); Novartis (Inst); Olympus (Inst); St. Jude Medical (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); W.L. Gore & Associates (Inst)
 
Hiroaki Miyata
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Kaketsuken (Inst); NIPRO CORPORATION (Inst); Novartis (Inst); Olympus (Inst); St. Jude Medical (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); W.L. Gore & Associates (Inst)
 
Takayuki Kinoshita
No Relationships to Disclose
 
Yutaka Tokuda
Honoraria - AstraZeneca; Chugai Pharma; Covidien; Daiichi Sankyo; Eisai; Fuji Pharma; GlaxoSmithKline; Kyowa Hakko Kirin; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical; Takeda